Evaluating a new imaging agent for cancer detection
68Ga-FAP-CHX PET/CT : Dosimetry and Preliminary Clinical Translational Studies
This study tests a new imaging agent to see if it can help find cancer better than current methods in patients with different types of cancer.
Quick facts
| Phase | Phase1; Phase2 |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | First Affiliated Hospital of Fujian Medical University Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Fuzhou, Fujian) |
| Trial ID | NCT05506566 on ClinicalTrials.gov |
What this trial studies
This study investigates the safety and effectiveness of a novel imaging agent, 68Ga-FAP-CHX, in patients with various types of cancer. It aims to assess the biodistribution, pharmacokinetics, and radiation dosimetry of this agent, comparing its performance to existing imaging methods like 68Ga-FAPI-04 and 18F-FDG PET/CT scans. The research focuses on understanding how well this new tracer can identify tumors and guide targeted therapies.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 to 75 with various solid tumors that have not been surgically treated.
Not a fit: Patients who are pregnant or unable to provide informed consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance cancer imaging techniques, leading to better diagnosis and treatment planning for patients.
How similar studies have performed: Other studies have shown promising results with similar FAP-targeted imaging approaches, indicating potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 18 years \< Age \< 75 years * Various solid tumors with available histopathological findings, and have not been treated surgically. * Signed informed consent. Exclusion Criteria: * patients with pregnancy * the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.
Where this trial is running
Fuzhou, Fujian
- Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical University — Fuzhou, Fujian, China (Recruiting)
Study contacts
- Study coordinator: Weibing Miao, MD
- Email: miaoweibing@126.com
- Phone: 86-0591-87981618
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.